The Use of Bronchial Rheoplasty in Emphysema Patients Previously Treated with Endoscopic Lung Volume Reduction: A Case Series.

IF 2.7 3区 医学 Q2 RESPIRATORY SYSTEM International Journal of Chronic Obstructive Pulmonary Disease Pub Date : 2024-08-05 eCollection Date: 2024-01-01 DOI:10.2147/COPD.S469214
Kristine Jensen, Thomas Egenod, Daniel P Franzen, Michael Perch
{"title":"The Use of Bronchial Rheoplasty in Emphysema Patients Previously Treated with Endoscopic Lung Volume Reduction: A Case Series.","authors":"Kristine Jensen, Thomas Egenod, Daniel P Franzen, Michael Perch","doi":"10.2147/COPD.S469214","DOIUrl":null,"url":null,"abstract":"<p><p>Endoscopic lung volume reduction (ELVR) is an established treatment option for patients with severe emphysema. Not all patients are candidates for this type of intervention, and in the context of significant airway secretions, they may be excluded from treatment. Bronchial Rheoplasty (BR) was developed to treat mucus hypersecretion by delivering nonthermal pulsed electric fields to the airway epithelium and submucosa. The literature to date demonstrates that patients treated with BR in clinical studies have a reduction in airway goblet cell hyperplasia as well as substantive clinical improvement in the setting of chronic bronchitis (CB). In this case series, we present four patients treated at three different institutions who had previously undergone ELVR with beneficial outcome. However, over time, these patients subsequently developed worsening clinical issues, including complaints of increased and thickened mucus, along with exacerbations in the setting of a loss of some ELVR-associated benefits. These patients then underwent exploratory treatment with BR with the intent of reducing their secretion burden and potentially restoring the efficacy associated with the initial placement of the airway valves. All BR procedures were well tolerated, and three of the four patients showed substantial improvement in their symptom burden. Airway examinations during the second of the two BR procedures also revealed what appeared to be less airway mucosal inflammation and a decrease in the quantity of airway secretions. Therefore, treatment with BR may have the potential to improve and restore the initial benefits associated with ELVR, thus enhancing long-term outcomes. Further clinical studies with sufficient follow-up are warranted to assess this in a larger cohort of patients, and to determine whether treatment with BR prior to ELVR may make more patients eligible for this treatment through reduction in their secretions and/or symptoms.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"19 ","pages":"1791-1797"},"PeriodicalIF":2.7000,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11313571/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Chronic Obstructive Pulmonary Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/COPD.S469214","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Endoscopic lung volume reduction (ELVR) is an established treatment option for patients with severe emphysema. Not all patients are candidates for this type of intervention, and in the context of significant airway secretions, they may be excluded from treatment. Bronchial Rheoplasty (BR) was developed to treat mucus hypersecretion by delivering nonthermal pulsed electric fields to the airway epithelium and submucosa. The literature to date demonstrates that patients treated with BR in clinical studies have a reduction in airway goblet cell hyperplasia as well as substantive clinical improvement in the setting of chronic bronchitis (CB). In this case series, we present four patients treated at three different institutions who had previously undergone ELVR with beneficial outcome. However, over time, these patients subsequently developed worsening clinical issues, including complaints of increased and thickened mucus, along with exacerbations in the setting of a loss of some ELVR-associated benefits. These patients then underwent exploratory treatment with BR with the intent of reducing their secretion burden and potentially restoring the efficacy associated with the initial placement of the airway valves. All BR procedures were well tolerated, and three of the four patients showed substantial improvement in their symptom burden. Airway examinations during the second of the two BR procedures also revealed what appeared to be less airway mucosal inflammation and a decrease in the quantity of airway secretions. Therefore, treatment with BR may have the potential to improve and restore the initial benefits associated with ELVR, thus enhancing long-term outcomes. Further clinical studies with sufficient follow-up are warranted to assess this in a larger cohort of patients, and to determine whether treatment with BR prior to ELVR may make more patients eligible for this treatment through reduction in their secretions and/or symptoms.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
在曾接受内窥镜肺容积缩小术治疗的肺气肿患者中使用支气管成形术:病例系列。
内窥镜肺容积缩小术(ELVR)是治疗严重肺气肿患者的一种成熟疗法。但并非所有患者都适合这种治疗方法,如果患者气道分泌物较多,可能会被排除在治疗范围之外。支气管流变成形术(Bronchial Rheoplasty,BR)通过向气道上皮和粘膜下层输送非热脉冲电场来治疗粘液分泌过多。迄今为止的文献表明,在临床研究中,接受气道流变成形术治疗的患者气道上皮细胞增生减少,慢性支气管炎(CB)的临床症状也得到明显改善。在本病例系列中,我们介绍了在三个不同机构接受过 ELVR 治疗的四名患者,他们之前都曾接受过 ELVR 治疗,并取得了良好的疗效。然而,随着时间的推移,这些患者随后出现了临床问题恶化,包括主诉粘液增多和变稠,以及在失去 ELVR 相关益处的情况下病情加重。随后,这些患者接受了BR探索性治疗,目的是减轻分泌物负担,并有可能恢复最初放置气道瓣膜时的疗效。所有 BR 治疗过程的耐受性都很好,四名患者中有三人的症状明显改善。在两次气道瓣膜置换术中的第二次手术中,气道检查也显示气道粘膜炎症似乎有所减轻,气道分泌物的数量也有所减少。因此,BR 治疗有可能改善和恢复 ELVR 最初带来的益处,从而提高长期疗效。我们有必要进行进一步的临床研究和充分的随访,以便在更大的患者群体中进行评估,并确定在进行 ELVR 之前使用 BR 治疗是否可以通过减少分泌物和/或症状使更多患者符合接受这种治疗的条件。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
4.80
自引率
10.70%
发文量
372
审稿时长
16 weeks
期刊介绍: An international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus will be given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management protocols. This journal is directed at specialists and healthcare professionals
期刊最新文献
Associations Between Physical Activity and Preserved Ratio Impaired Spirometry: A Cross-Sectional NHANES Study. Red Blood Cell Distribution Width/Hematocrit Ratio: A New Predictor of 28 Days All-Cause Mortality of AECOPD Patients in ICU. Emerging Anti-Inflammatory COPD Treatments: Potential Cardiovascular Impacts. The Incidence, Risk Factors, and Predictive Model of Obstructive Disease in Post-Tuberculosis Patients. A Qualitative Study on Illness Perception and Coping Behaviors Among Patients with Chronic Obstructive Pulmonary Disease: Implications for Intervention.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1